Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair
12 Marzo 2024 - 1:00PM
Business Wire
Allurion Technologies, Inc. (NYSE: ALUR), a company
dedicated to ending obesity, today announced the appointment of its
newest board member and Audit Committee Chair, Milena
Alberti-Perez, effective as of March 11, 2024.
"Milena joins the Allurion board during an exciting time in the
company’s history and is a proven and dynamic leader, with deep
experience as an operator and board member," said Dr. Shantanu
Gaur, Allurion Founder and CEO. "Her perspective and guidance will
be invaluable as Allurion furthers its mission to treat the one
billion people around the world with obesity.”
Ms. Alberti-Perez previously served as Chief Financial Officer
at Getty Images (NYSE: GETY) and CFO at Penguin Random House where
she oversaw a global business generating over $3 billion in annual
sales. She currently serves as Chair of the Audit Committee at
Digimarc Corporation (Nasdaq: DMRC) and Chair of the Finance
Committee and member of the Audit Committee at Pitney Bowes
(NASDAQ: PBI)
“I am thrilled to join Allurion at a pivotal stage of its
journey as a public company,” said Ms. Alberti-Perez. “I am looking
forward to working with my fellow board members and the company’s
management team as Allurion embarks on setting a new standard for a
best-in-class weight loss experience.”
Ms. Alberti-Perez holds a B.A. from the University of
Pennsylvania and an M.B.A. from Harvard Business School.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Iris AI Platform, and the
Allurion Connected Scale. The Allurion Virtual Care Suite is also
available to providers separately from the Allurion Program to help
customize, monitor, and manage weight-loss therapy for patients
regardless of their treatment plan, whether it is gastric balloon,
surgical, medical or nutritional. The Allurion Gastric Balloon is
an investigational device in the United States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240312538837/en/
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investor Contact Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Grafico Azioni Allurion Technologies (NYSE:ALUR)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Allurion Technologies (NYSE:ALUR)
Storico
Da Dic 2023 a Dic 2024